Minovia announces FDA Fast Track, RPD designations to MNV-201

Minovia Therapeutics announces that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to the Company’s lead investigational compound, MNV-201. The FDA has also granted Rare Pediatric Disease, RPD, Designation to MNV-201, which is in Phase 2 clinical trials for the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting children.